When Did Human Biological Waste Become the Next Oil

When did human biological waste become the next oil?

Kanvas Biosciences raised $48 million last week to commercialize the gut bacteria of a 76-year-old woman who beat stage 4 colorectal cancer with Keytruda. The company calls it "capturing lightning in a bottle." The law calls it property. The difference matters more than the press release lets on.

The science behind Kanvas is real and the ambition is legitimate. The Princeton-based company has built a platform that maps microbial ecosystems inside the gut using a proprietary imaging technique called HiPR-FISH, then engineers those ecosystems into standardized live biotherapeutic products. Their lead candidate, KAN-001, is an oral pill containing roughly 50 bacterial strains isolated from the MD Anderson patient whose cancer disappeared after she received a microbiome transplant and Keytruda together. The same approach produced a complete response in a colorectal cancer patient who had run out of options. That is not nothing. That is a signal worth following.

But the more interesting story is what the company is actually building: an intellectual property apparatus organized around the commodification of exceptional human biology.

The legal framework is not new. The 1990 California Supreme Court ruling in Moore v. Regents of the University of California established that a patient has no property interest in cells or tissues once they leave the body, provided consent was obtained. The donor of Kanvas's founding bacterial consortium signed away whatever rights she had when she consented to the use of her stool for research and commercialization. This is standard practice across the microbiome sector. Vedanta Biosciences, Seres Therapeutics, and Finch Therapeutics all operate on the same legal footing. What is less standard is the specificity of what Kanvas has built around that precedent: a full-stack platform that starts with spatial imaging of microbial communities, uses AI to identify which strains matter, and ends with GMP-manufactured anaerobic consortia produced in-house rather than outsourced.

Most microbiome companies are still doing fecal transplants in various wrappers. Kanvas is attempting to do what pharmaceutical manufacturing did for insulin: take something biological and messy and turn it into something standardized, dosable, and repeatable. Whether they can actually achieve that is the open question. The Phase 1 trial for KAN-001 in non-small cell lung cancer is targeting enrollment as early as September. Response rates for checkpoint inhibitors currently sit between 20 and 40 percent of patients. Doubling that, as the company has suggested it hopes to do, would be a genuine clinical advance. It is also exactly what every microbiome-oncology company has claimed, and the track record is mixed.

The company's other programs are earlier. KAN-004 is already in a Phase 1 trial for colitis caused by checkpoint inhibitors themselves, a real quality-of-life problem for cancer patients who have to stop immunotherapy because the treatment is working too well. That one has a clearer near-term path. A Gates Foundation-funded project to develop a fully synthetic microbiome replacement for maternal environmental enteric dysfunction, a debilitating gut condition affecting roughly 150 million people primarily in South Asia and Sub-Saharan Africa, is genuinely ambitious and several years from anything resembling a product.

Stephen Quake, the Stanford bioengineer who pioneered microfluidics for DNA sequencing and served as chief science advisor at the Chan Zuckerberg Initiative, joined the board in connection with this round. That is a credential worth noting. Quake does not lend his name to companies he thinks are toys.

The hype risk here is real and the reporters covering this beat have seen it before. Microbiome science has a documented history of promising more than it delivered in the 2010s, when every gut bacteria finding was going to cure autoimmune disease, depression, and obesity simultaneously. The field cleaned up its act and produced some real results, but the incentive to oversell a single exceptional responder remains high. One patient whose cancer went into remission after microbiome intervention does not make a drug. The difference between a proof-of-concept and a product is a Phase 1 trial, and Phase 1 trials fail more often than they succeed.

What Kanvas has that is genuinely different from a standard fecal transplant startup is vertical integration. They built their own GMP anaerobic fermentation facility in South San Francisco because, as any microbiologist will tell you, growing anaerobic bacteria at scale without contamination is a hard manufacturing problem. Most competitors outsource it. Kanvas decided that the manufacturing process is part of the IP, and that is a defensible strategic call if they can execute.

The biological ownership question that the company's founding raises is worth sitting with, though. The woman whose gut bacteria now exist as a patent-protected bacterial consortium, manufactured in a facility in South San Francisco and being developed as a drug for lung cancer patients she will never meet, signed a consent form. She may or may not have received any compensation beyond the reimbursement of expenses for her stool donation. The legal precedent is clear. The ethical and philosophical questions about whether that is the right framework for an emerging class of medicines derived from exceptional human biology are not answered and deserve more attention than the press release will give them.

Matt Cheng, the CEO and an infectious disease doctor by training, said in the company's announcement that the opportunity to help so many people through the Gates Foundation work was both a privilege and a responsibility. That framing is probably sincere. It also illustrates the tension at the heart of the microbiome biotech boom: the people whose bodies produce the most valuable biological materials are almost never the people who capture the value.

The company presented preliminary KAN-001 data at the 2025 Society for Immunotherapy of Cancer annual meeting. The presentation showed evidence of microbial engraftment and preliminary safety data, though the results have not yet been published in a peer-reviewed journal.

Kanvas has now raised $78 million total, including the new $48M Series A, putting it among the better-capitalized microbiome companies in the oncology space.

The story is not that Kanvas is doing something unethical. The legal framework is settled and the science is promising. The story is that the biotech industry has quietly built an economy in which the body's most disposable outputs its waste can become the foundation for $78 million drug platforms, and nobody has asked what that means for how we think about biological ownership in the age of programmable medicine.

That is the question worth asking while the Phase 1 trial is running.